PreveCeutical™ Medical Inc. Signs Letter of Intent with UniQuest Pty Limited for Research & Development Program Engineering Peptide Therapeutics for Non-Addictive Analgesics
- Category: More News
- Published on Tuesday, 08 August 2017 09:44
- Hits: 794
VANCOUVER, Canada I August 08, 2017 I PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE:PREV) (FSE:18H) announces that on August 7, 2017, the Company signed a non-binding letter of intent (“LOI”) with UniQuest Pty Limited (“UniQuest”) which describes the essential terms and conditions of a proposed research collaboration between PreveCeutical and The University of Queensland.
The LOI is related to a Research and Development (“R&D”) program involving peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide R&D program.
Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is expected to undergo an expansion in the foreseeable future.
In this regard, a team led by Dr. Harendra (Harry) Parekh in-conjunction with fellow collaborators at The University of Queensland (“UQ”) propose to expand the use of their disulfide linker technology to develop non-addictive analgesics for moderate-to-severe pain.
PreveCeutical and UniQuest are currently negotiating and preparing the definitive agreement regarding the collaboration.
PreveCeutical’s Chairman and CEO, Mr. Stephen Van Deventer commented, “We are very pleased to be partnered with UniQuest and the University of Queensland on this innovative research program. The development of non-addictive analgesics is very complementary to our focus on utilising nature and science for the benefit of health-conscious consumers. We look forward to moving this project forward into the next phases of development.”
“The proposed R&D program will serve to expand and expedite development of promising lead peptide candidates and facilitate the engagement of highly experienced collaborators to demonstrate proof-of-concept through pharmacological, pharmacokinetic and in vivo evaluation in appropriate models of pain and inflammation,” commented Dr. Parekh, UQ researcher and Chief Research Officer at PreveCeutical Medical Inc.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a biomedical company that coined the platform for preventive health sciences. PreveCeutical’s innovative research and development department advances organic and Nature Identical products for both prevention and curative therapies.
The Company currently has one product available for sale, the CELLB9® Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.
About UniQuest Pty Limited
UniQuest specializes in the commercialization of intellectual property, research outcomes and expertise developed by UQ and is the principal commercialization company of UQ. UniQuest benchmarks in the top ten percent globally for university-based technology transfers and UQ innovations licensed by UniQuest are now generating annual sales of over AUD $3 billion. For example, UQ superconductor technology, through licensing arrangements, is used in two-thirds of the world’s MRIs and more than 80 million doses of the life-saving Gardasil® cervical cancer vaccine, patented by UniQuest in 1991, have been distributed throughout 121 countries, including 72 developing countries.
SOURCE: PreveCeutical Medical